Madison, WI-based Deltanoid Pharmaceuticals has named former Genzyme executive Douglas Jermasek as its new CEO. Jermasek will replace Hector DeLuca, who has spent his life researching Vitamin D and building companies based on the compound. Xconomy profiled DeLuca and Deltanoid in late 2014. DeLuca becomes Deltanoid’s chairman, president and COO.
Author: Alex Lash
I've spent nearly all my working life as a journalist. I covered the rise and fall of the dot-com era in the second half of the 1990s, then switched to life sciences in the new millennium. I've written about the strategy, financing and scientific breakthroughs of biotech for The Deal, Elsevier's Start-Up, In Vivo and The Pink Sheet, and Xconomy.
View all posts by Alex Lash
